| The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years. | |
| | |
MedLine Citation:
|
PMID: 21274515 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Many osteoporotic women prescribed strontium ranelate have previously received bisphosphonates. Prior bisphosphonate use blunted the spinal bone mineral density (BMD) response for 6 months. Hip BMD was blunted to a degree for 2 years, although there was an overall increase in hip BMD in contrast to the heel where BMD did not increase. INTRODUCTION: Many osteoporotic women commenced on strontium ranelate have already received treatment with bisphosphonates. This study investigates whether prior bisphosphonate use impairs the subsequent therapeutic response to strontium ranelate. METHODS: Women were recruited who were either bisphosphonate naïve or currently receiving a bisphosphonate. All women received strontium ranelate and were followed up for 2 years. RESULTS: One hundred and twenty women were recruited. After 2 years, the bisphosphonate-naïve group had significant BMD increases of 8.9%, 6.0% and 6.4% at the spine, hip and heel, respectively. In the prior bisphosphonate group, BMD increased significantly at the spine (4.0%) and hip (2.5%) but not at the heel. At all time points at all sites, the BMD increase was greater in the bisphosphonate-naïve group. BMD at the spine did not increase during the first 6 months in the prior bisphosphonate group but then increased in parallel with the bisphosphonate-naïve group. In contrast, the difference between the two groups in hip BMD continued to increase throughout the 2 years. P1NP was suppressed in the prior bisphosphonate group for the first 6 months. CONCLUSIONS: After bisphosphonate exposure, the BMD response to strontium ranelate is blunted for only 6 months at the spine. At the hip, a degree of blunting was observed over 2 years, although there was an overall increase in hip BMD in contrast to the heel where no increase in BMD was observed. |
| | |
Authors:
|
E T Middleton; S A Steel; M Aye; S M Doherty |
Related Documents
:
|
22150035 - Three months of rifapentine and isoniazid for latent tuberculosis infection. 21195985 - Significant hypercapnia either in co(2)-insufflated or air-insufflated colonoscopy unde... 21466965 - A retrospective non-randomized study on the impact of integuseal, a preoperative microb... 21122285 - Treatment of lesions of the rotator cuff. 10491055 - Successful treatment of spider leg veins with a high-energy, long-pulse, frequency-doub... 10323715 - Ruby laser-assisted hair removal success in relation to anatomic factors and melanin co... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-1-28 |
Journal Detail:
|
Title: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA Volume: - ISSN: 1433-2965 ISO Abbreviation: - Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-1-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9100105 Medline TA: Osteoporos Int Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Centre for Metabolic Bone Disease, Hull Royal Infirmary, Brocklehurst Building, 220-236 Anlaby Road, Hull, HU3 2RW, UK, etmiddleton@doctors.org.uk. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Validation, reliability, and responsiveness of Prolapse Quality of Life Questionnaire (P-QOL) in a B...
Next Document: Development of a fluorophore-ribosomal DNA restriction typing method for monitoring structural shift...